EP1636163A1 - Procede de preparation de gabapentine - Google Patents
Procede de preparation de gabapentineInfo
- Publication number
- EP1636163A1 EP1636163A1 EP03816962A EP03816962A EP1636163A1 EP 1636163 A1 EP1636163 A1 EP 1636163A1 EP 03816962 A EP03816962 A EP 03816962A EP 03816962 A EP03816962 A EP 03816962A EP 1636163 A1 EP1636163 A1 EP 1636163A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gabapentin
- acid addition
- addition salt
- alcohol
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
Definitions
- the present invention relates to the process for the preparation of anhydrous Gabapentin of pharmaceutical grade from the Gabapentin acid addition salts. More particularly, the present invention relates to a process for the preparation of anhydrous gabapentin form II from Gabapentin hydrochloride or Gabapentin hydrobromide salt. BACKGROUND OF THE INVENTION
- Gabapentin is l-(aminomethyl)cyclohexaneacetic acid having the chemical structure of formula (I).
- the U.S. Pat. No. 4,894,476 described a method to prepare essentially the same anhydrous Gabapentin described in the U.S. Pat. No. 4,024,175 through pure Gabapentin monohydrate of defined physical characteristics.
- the process described in this patent comprises of: a) pouring a solution of an acid salt of l-(aminomethyl)cyclohexaneacetic acid in deionised water onto an ion exchange column in the basic form and eluting the column with deionized water; b) concentrating the elute producing a slurry; c) cooling and adding alcohol to the slurry from step (b); d) cooling and centrifuging the slurry from step (c); e) drying the precipitate to obtain Gabapentin monohydrate, f) The Gabapentin monohydrate was then dissolved in methanol and diluted with isopropyl alcohol to produce a slurry. The slurry was then centrifuged and the precipitate
- the PCT international publication WO 00/01660 described a method to prepare the anhydrous Gabapentin from Gabapentin hydrochloride.
- the method described in this publication consists of, treating the hydrochloride salt with ion exchange resin, and the aqueous solution thus obtained was concentrated to certain level and the left over water was removed by azeotropic distillation. Further the mass was diluted with isopropyl alcohol and cooled to get anhydrous Gabapentin crystallized from the mass.
- Another PCT international publication WO 00/58268 described a method to prepare the anhydrous Gabapentin from Gabapentin hydrochloride.
- the method described in this publication consisted of, treating the hydrochloride salt aqueous solution with a base to Gabapentin isoelectric point and then diafiltering the solution through highly selective membrane to separate chloride ion and Gabapentin substantially free from chloride ions.
- the PCT international publication WO 02/34709 described a process for the purification of Gabapentin hydrochloride from the inorganic salts and its conversion into Gabapentin by treatment of an aqueous Gabapentin hydrochloride solution with a cation exchange resin.
- the object of the present invention was therefore to develop a simple and viable alternate method to produce anhydrous Gabapentin form II, starting from Gabapentin acid addition salts.
- the present invention provides a novel method to prepare anhydrous Gabapentin form II from Gabapentin acid addition salts such as Gabapentin hydrochloride and Gabapentin hydrobromide.
- the process consists of neutralizing the said acid addition salts with an organic base in water to get an aqueous solution comprising of Gabapentin and amine acid addition salt dissolved in water.
- the process further comprises of a method to separate the Gabapentin and the amine acid addition salt from such an aqueous solution and to recover Gabapentin as an anhydrous Gabapentin form II.
- the preferred embodiment of the present invention provides a method for preparing anhydrous gabapentin form II comprising: (a) dissolution of Gabapentin acid addition salt in water, (b) neutralization of the acid addition salt with a base to get a aqueous solution comprising of Gabapentin and amine acid addition salt dissolved in water, (c) distillation of water from the solution obtained in step (b) under reduced pressure, (d) seeding the concentrate with Gabapentin form II at an appropriate instance during said distillation to initiate the crystallization of Gabapentin form II while the solution is being concentrated, (e) addition of alcohol or mixture of alcohols in to the concentrate to enable the amine acid addition salt dissolved in it, (f) recovery of the crystallized Gabapentin form II from the mixture by filtration and (g) purification of the product by recrystallization from a solvent.
- the Gabapentin acid addition salt in step (a) is inorganic acid addition salt such as hydrochloride or hydrobromide salts of gabapentin and like.
- the said acid addition salt is dissolved in water to get an aqueous solution.
- the dissolution is preferably carried out with 2 to 5 times the weight of water in proportion to the Gabapentin acid addition salt.
- the dissolution is carried out at a temperature between 20 to 50°C and preferably at 25 to 30°C.
- the neutralization step (b) is carried out with base, preferably with organic bases, such as amines.
- the preferred amines are primary, secondary and tertiary alkyl amines. The most preferred amines are triethylamine, tripropyl amine and tributylamine.
- 0.9 to 1.2 mole equivalence of amines is used, preferably 0.95 to 1.05 mole equivalence of amine is used for the neutralization.
- the pH of the solution is 6.5 to 7.5 after the neutralization and the preferred pH of neutralization is 6.8 to 7.2.
- the neutralization step is earned out at a temperature ranging between 10- 50 ° C, preferably at a temperature ranging between 20-30 ° C to get an aqueous solution comprising of Gabapentin and amine acid addition salt dissolved in water.
- step-c water is removed from the aqueous solution by distillation under reduced pressure. Water is distilled at 30 to 70°C under reduced pressure, preferably at 45 to 55°C.
- step (d) Gabapentin from II seeds are added after distilling out 20 to 50% of water quantity used for the dissolution of the Gabapentin acid addition salt. How ever the appropriate seeding instance could vary with the temperature of the distillation and quantity of the water used in the process. The addition of Gabapentin form II seeds at this instance initiates the crystallization of Gabapentin form II during the water distillation.
- the Gabapentin form II seeds added are about 1 to 5 g for every 100 g of Gabapentin acid addition salt and preferably 2 g seeds for every 100 g of Gabapentin acid addition salt used in the process. Water distillation is continued till 80 to 95% quantity of water used for the dissolution of the Gabapentin acid addition salt is distilled out. A small sample is removed from the concentrate at this point and filtered, washed with chilled water and dried under vacuum. Examined the product obtained by IR (KBr) and X-ray diffraction, and it is identified to match with those recorded from Gabapentin form II.
- the concentrate is then diluted with alcohol or with mixture of alcohols in step (e) and then cooled to 0 to 20°C.
- the dilution with alcoholic solvent facilitates the dissolution of the amine acid addition salts in the solvent and removal from the concentrate so as to enable the separation of Gabapentin form the amine acid addition salts.
- the preferred alcohols are methyl alcohol, ethyl alcohol, isopropyl alcohol and butyl alcohol or their mixture of one in another.
- the preferred alcohol mixture ia a mixture of methyl alcohol and isopropyl alcohol.
- the slurry obtained from step (e) is then filter and washed with the solvent to get the product Gabapentin form II.
- a sample from the product is again re-examined by IR (KBr) and X-ray diffraction and it is identified to match with those recorded from Gabapentin form II.
- the product is then recrystallized from methyl alcohol or ethyl alcohol to obtain a pure product with anion content less than 100 ppm by silver nitrate solution titration or by ion chromatography and lactam impurity of formula (II) content less than 0.1% wt/wt by HPLC analysis.
- Gabapentin hydrobromide is dissolved in twice the weight of water at 25 to 30°C to get an aqueous solution.
- the aqueous solution is then neutralized with tributylamine at 25 to 30°C over a period of 30 min.
- the solution is then stirred at 25 to 30°C over a period of 30 min.
- the aqueous solution is then heated to 45 to 50°C and distilled out 35% of water under reduced pressure.
- Added Gabapentin form II seed crystals to the solution and continued the water distillation to the extent of around 90% of the total water used for the dissolution of the gabapentin salt in the process.
- the concentrate is then diluted with a mixture of methyl alcohol and isopropyl alcohol.
- the slurry so obtained is then cooled to 0 to 5°C and filtered.
- the product is then recrystallized from methyl alcohol.
- Gabapentin hydrobromide 200 g, 0.793 mole was dissolved in water (400 ml) at 30° C. Into this solution was added tributylamine (154 g, 0.83 mole) at 25-30° C. The ⁇ H of the solution was 6.9 at the end of tributylamine addition. The solution was then warmed to 50°C and distilled out water at 45 to 50°C at 35 to 40 mm Hg. Added in to the content, Gabapentin form II seeds (4 g) when water (160 ml) was distilled out from the solution. Continued the distillation at 45 to 50°C at 35 to 34 mm Hg till water (360 ml) was collected.
- Gabapentin hydrobromide 200 g, 0.793 mole was dissolved in water (400 ml) at 30° C. Into this solution was added tributylamine (154 g, 0.83 mole) at 25-30° C. The p H of the solution was 6.9 at the end of tributylamine addition. The solution was then warmed to 50°C and distilled out water at 45 to 50°C at 35 to 40 mm Hg. Added in to the content Gabapentin form II seeds (4 g) when water (140 ml) was distilled out. Continued the distillation at 45 to 50°C at 35 to 34 mm Hg till water (360 ml) was collected.
- Gabapentin hydrobromide 50 g, 0.198 mole was dissolved in water (100 ml) at 30° C. Into this solution was added tributylamine (38.5 g, 0.207 mole) at 25-30° C. The ⁇ H of the solution was 6.8 at the end of tributylamine addition. The solution was then warmed to 50°C and distilled out water at 45 to 50°C at 35 to 40 mm Hg. Added in to the content Gabapentin form II seeds (1 g) when water (35 ml) was distilled out. The distillation was continued till water (85 ml) was collected.
- Gabapentin hydrobromide (100 g, 0.396 mole ) was dissolved in water (200 ml) at 30° C. Into this solution was added tributylamine (77 g, 0.415 mole) at 25-30° C. The p H of the solution was 7.13 at the end of tributylamine addition. The solution was then warmed to 50°C and distilled out water at 45 to 50°C at 35 to 40 mm Hg. Added in to the content Gabapentin form II seeds (2 g) when water (100 ml) was distilled out. Continued the distillation at 45 to 50°C at 35 to 34 mm Hg till water (180 ml) was collected.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne le processus de préparation de Gabapentine anhydre de qualité pharmaceutique à partir de sels d'addition d'acides de Gabapentine. Le processus consiste à neutraliser lesdits sels d'addition d'acides avec une base organique dans l'eau pour obtenir une solution aqueuse contenant de la Gabapentine et un sel d'addition d'acide aminé dissous dans l'eau. Le procédé comprend aussi un procédé pour séparer la Gabapentine et le sel d'addition d'acide aminé à partir de cette solution aqueuse et pour récupérer la Gabapentine sous forme de Gabapentine anhydre forme II.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN416CH2003 | 2003-05-19 | ||
PCT/IN2003/000246 WO2004101489A1 (fr) | 2003-05-19 | 2003-07-21 | Procede de preparation de gabapentine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1636163A1 true EP1636163A1 (fr) | 2006-03-22 |
EP1636163A4 EP1636163A4 (fr) | 2006-08-09 |
Family
ID=33446372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03816962A Withdrawn EP1636163A4 (fr) | 2003-05-19 | 2003-07-21 | Procede de preparation de gabapentine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1636163A4 (fr) |
AU (1) | AU2003259544A1 (fr) |
WO (1) | WO2004101489A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0415076D0 (en) * | 2004-07-05 | 2004-08-04 | Sandoz Ind Products S A | Process for the preparation of gabapentin |
WO2009015685A1 (fr) | 2007-07-27 | 2009-02-05 | Medichem, S.A. | Procédé de préparation de la forme polymorphe ii de la gabapentine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002044123A1 (fr) * | 2000-12-01 | 2002-06-06 | Erregierre S.P.A. | Procede de preparation d'acide cyclohexaneacetique 1-(aminomethyl) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6255526B1 (en) * | 1996-12-24 | 2001-07-03 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
ITMI20012750A1 (it) * | 2001-12-21 | 2003-06-21 | Procos Spa | Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura |
-
2003
- 2003-07-21 EP EP03816962A patent/EP1636163A4/fr not_active Withdrawn
- 2003-07-21 AU AU2003259544A patent/AU2003259544A1/en not_active Abandoned
- 2003-07-21 WO PCT/IN2003/000246 patent/WO2004101489A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002044123A1 (fr) * | 2000-12-01 | 2002-06-06 | Erregierre S.P.A. | Procede de preparation d'acide cyclohexaneacetique 1-(aminomethyl) |
Non-Patent Citations (1)
Title |
---|
See also references of WO2004101489A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003259544A1 (en) | 2004-12-03 |
WO2004101489A1 (fr) | 2004-11-25 |
EP1636163A4 (fr) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0024210B1 (fr) | Procédé pour la production de thréo-3-(3,4-dihydroxyphényl) serine optiquement active et produit ainsi obtenu | |
US6518456B1 (en) | Process for the production of 1-(aminomethyl)-cyclohexyl-acetic acid in pure form | |
EP1165489B1 (fr) | Procede de preparation de gabapentine | |
US7393974B2 (en) | Process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid | |
US6846950B2 (en) | Process for synthesis of 1-(aminomethyl)cyclohexane acetic acid hydrochloride | |
WO2004101489A1 (fr) | Procede de preparation de gabapentine | |
US20070043236A1 (en) | Process for preparation of gabapentin | |
US7071356B1 (en) | Process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid | |
EP0611369A1 (fr) | Procede de preparation (s) (+)-4,4'-(1-methyl-1,2-ethanediyl-bis-(2,6-piperazinedione) | |
US7635717B2 (en) | Process for the preparation of amino methyl cyclo alkane acetic acids | |
CN110655535A (zh) | 一种替诺福韦的纯化方法 | |
US7439387B2 (en) | Process for the preparation of Gabapentin form-II | |
EP1727784B1 (fr) | Procede ameliore pour la preparation de gabapentine | |
EP1765767A1 (fr) | Methode servant a preparer gabapentine | |
JP4109446B2 (ja) | ジアステレオ異性体として純粋なトランス−2−[(α−メチルベンジル)アミノ]シクロペンタノールの製造方法 | |
EP3031800B1 (fr) | Procédé pour la préparation de miglustat de haute pureté | |
EP3068746A1 (fr) | Procédé de préparation de 1-aminoindane énantiomériquement pur | |
JP2007297386A (ja) | ガバペンチンを製造するための方法 | |
EP3060544B1 (fr) | Procédé de préparation de gabapentine | |
JP2770512B2 (ja) | アミノエチルスルホン酸アルカリ金属塩類の精製方法 | |
WO2008132759A2 (fr) | Procédé industriellement avantageux de production de dihydrate de lisinoprile | |
WO2005117526A2 (fr) | Procede ameliore pour la purification de la gabapentine | |
JP2010006752A (ja) | 4−アミノシクロヘキサン−1−カルボン酸のシス/トランス異性体混合物の分離方法 | |
ITMI992023A1 (it) | Procedimento per la preparazione e purificazione del tramadol | |
JPH06100502A (ja) | 光学活性1−(1−ナフチル)エチルアミンの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051130 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060706 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090203 |